Lexicon Pharmaceuticals (LXRX) Cut to “Strong Sell” at BidaskClub

Lexicon Pharmaceuticals (NASDAQ:LXRX) was downgraded by BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued on Wednesday.

A number of other equities research analysts have also recently issued reports on the stock. Citigroup decreased their price objective on shares of Lexicon Pharmaceuticals from $27.00 to $26.00 and set a “buy” rating for the company in a report on Friday, November 2nd. ValuEngine cut shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 17th. Cowen reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Friday, November 2nd. Gabelli reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Friday, November 2nd. Finally, Zacks Investment Research cut shares of Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 7th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $25.25.

Lexicon Pharmaceuticals stock opened at $7.44 on Wednesday. The company has a debt-to-equity ratio of 8.85, a quick ratio of 2.83 and a current ratio of 2.90. Lexicon Pharmaceuticals has a 12 month low of $7.04 and a 12 month high of $13.97. The firm has a market cap of $858.00 million, a PE ratio of -5.86 and a beta of 0.74.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.33) by $0.07. The firm had revenue of $6.90 million during the quarter, compared to analysts’ expectations of $12.56 million. Lexicon Pharmaceuticals had a negative net margin of 168.23% and a negative return on equity of 1,247.65%. Lexicon Pharmaceuticals’s revenue for the quarter was down 74.3% on a year-over-year basis. During the same period in the prior year, the company posted ($0.29) earnings per share. As a group, equities analysts expect that Lexicon Pharmaceuticals will post -1.29 earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in LXRX. Schwab Charles Investment Management Inc. lifted its stake in shares of Lexicon Pharmaceuticals by 6.4% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 241,061 shares of the biopharmaceutical company’s stock valued at $2,893,000 after purchasing an additional 14,426 shares during the last quarter. BlackRock Inc. lifted its stake in shares of Lexicon Pharmaceuticals by 4.6% in the 2nd quarter. BlackRock Inc. now owns 4,422,293 shares of the biopharmaceutical company’s stock valued at $53,066,000 after purchasing an additional 195,461 shares during the last quarter. Tocqueville Asset Management L.P. acquired a new position in shares of Lexicon Pharmaceuticals in the 2nd quarter valued at $164,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Lexicon Pharmaceuticals in the 2nd quarter valued at $205,000. Finally, Northern Trust Corp lifted its stake in shares of Lexicon Pharmaceuticals by 2.1% in the 2nd quarter. Northern Trust Corp now owns 584,393 shares of the biopharmaceutical company’s stock valued at $7,013,000 after purchasing an additional 12,289 shares during the last quarter.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Featured Article: Find a Trading Strategy That Works

Analyst Recommendations for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit